SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today ...
Recludix Pharma has launched with $60 million in series A funding to use DNA-encoded libraries to discover small-molecule drugs. The start-up’s focus is on inhibiting SH2 domains, protein structures ...
Financing led by institutional investors, with participation from new investor Eli Lilly and Company Inclusive of this investment, a total of $123 million in equity financing received from ...
The MarketWatch News Department was not involved in the creation of this content. -- Financing led by institutional investors, with participation from new investor Eli Lilly and Company -- Inclusive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results